Investing
2seventy bio to lay off 40% of workforce
© Reuters.
(Reuters) – 2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm’s cancer cell therapy Abecma.
The company will save about $130 million in 2024-25 as it eliminates 176 roles.
2seventy bio said it expects a decline in Abecma sales in the third quarter and U.S. revenue for the therapy in 2023 could be lower than the $470-$570 million range it previously projected.
The company added that CEO Nick Leschly will step down and transition to the role of chairman.
Read the full article here
-
Side Hustles3 days ago
Why the Best CEOs Think Like Anthropologists
-
Side Hustles6 days ago
LA Rental Prices Skyrocketing Despite Price Gouging Laws
-
Make Money4 days ago
Earn More in 2025: Top 10 High-Yield Savings Accounts Revealed
-
Side Hustles6 days ago
How to Craft Marketing Campaigns That Reach Multiple Generations
-
Side Hustles4 days ago
What to Do If TikTok is Banned — How to Protect Your Brand
-
Make Money5 days ago
Build Your Future: 5 Simple Steps to Financial Stability
-
Side Hustles4 days ago
10 Roles That Are Surprisingly Well-Suited for Outsourcing
-
Side Hustles5 days ago
Meta Is Laying Off 5% of Its Workforce: Read the Memo